CLINICAL_TRIALS trial_result · 2012-03-27

Clinical Trial Update: Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC) [Phase 2]

Phase 2 trial update of axitinib as second-line treatment for metastatic renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2012-03-27